AxoGen, Inc.
NASDAQ:AXGNMedical - Devices
+$0.25 today
- Market cap
- $3.40B
- Beta
- 1.12
- P/E (TTM)
- -73.4
- EPS (TTM)
- -$0.61
Volume 2.11M
Average 1.08M
AXGN Total Current Assets
All assets expected to be converted to cash or used up within one year.
AxoGen, Inc.NASDAQ: AXGN
Total Current Assets · Q3 FY2026 · quarter ended Sep 2026
Total current assets rises 282.8% from a year ago
Total current assets stood at $438.09M at the end of Q3 FY2026, up 282.8% from a year earlier and up 118.6% from the prior quarter. Over 3 fiscal years it compounded at +7.1% a year.
Context
- Total current assets amounted to 79.6% of total assets at the end of Q3 FY2026, up 26.7 pp from a year earlier.
- Total current assets increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total current assets keeps rising in the next quarterly balance sheet after a +282.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Current Assets history
USD · from the balance sheet
- Latest · FY2025
- 120.42M USD
- Year-over-year change
- +21.4%
- 4-year CAGR
- -1.3%
| Period | Period end | Total Current Assets | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 120.42M | +21.4% |
| FY2024 | 2024-12-31 | 99.22M | +12.7% |
| FY2023 | 2023-12-31 | 88M | -10.3% |
| FY2022 | 2022-12-31 | 98.08M | -22.8% |
| FY2021 | 2021-12-31 | 127.05M | — |
Total Current Assets vs competitors
How AXGN compares with its peers on the latest reported figures
- AXGN's Sep 2026 total current assets of $438.09M is the highest of the 7 companies compared; the peer median is $63.11M.
- Its year-over-year change of +282.8% is the highest of 7, against a peer median of -9.9%.
- Total current assets amounts to 79.6% of total assets for AXGN, versus a peer median of 67.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $438.09M | +282.8% | +7.1% | 79.6% | |
| Mar 2026 | $268.5M | +0.1% | +17.6% | 51.6% | |
| Mar 2026 | $240.33M | +20.1% | +27.4% | 77.9% | |
| Mar 2026 | $63.6M | -13.7% | -24.0% | 57.5% | |
| Mar 2026 | $62.62M | -9.4% | +16.6% | 80.3% | |
| Jun 2026 | $54.49M | -10.3% | +6.6% | 91.2% | |
| Jun 2026 | $20.78M | -80.2% | +210.3% | 42.6% | |
| Peer median (excluding AXGN) | $63.11M | -9.9% | +17.1% | 67.7% | |
Competitors are the stored peer set for AXGN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 32.76M | 15.28M | 31.02M | 27.55M | 35.55M |
| Short-term Investments | 51.33M | 33.51M | 0 | 5.93M | 0 |
| Net Receivables | 18.16M | 22.19M | 25.15M | 24.11M | 26.17M |
| Inventory | 16.69M | 18.91M | 23.02M | 33.18M | 42.37M |
| Other Current Assets | 6.25M | 6.25M | 6M | 8.45M | 16.33M |
| Total Current Assets | 127.05M | 98.08M | 88M | 99.22M | 120.42M |
| Property, Plant & Equipment (Net) | 78.12M | 93.66M | 104.29M | 98.93M | 94.52M |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 2.86M | 3.65M | 4.53M | 5.58M | 6.75M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 0 | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 80.98M | 97.31M | 108.82M | 104.51M | 101.27M |
| Total Assets | 208.02M | 195.39M | 196.83M | 203.73M | 221.69M |
| Account Payables | 5.92M | 8.96M | 11.77M | 8.01M | 2.89M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 9.67M | 0 | 0 | 18.58M | 16.63M |
| Total Current Liabilities | 24.29M | 23.75M | 30.43M | 30.61M | 23.56M |
| Long-term Debt | 44.82M | 45.71M | 46.6M | 47.5M | 48.39M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 5.56M | 4.52M | 2.99M | 2.49M | 4.03M |
| Total Non-current Liabilities | 71.18M | 70.64M | 70.73M | 69.21M | 69.28M |
| Total Liabilities | 95.47M | 94.39M | 101.16M | 99.82M | 92.84M |
| Common Stock | 417K | 424K | 431K | 441K | 472K |
| Retained Earnings | (230.63M) | (259.58M) | (281.3M) | (291.26M) | (306.96M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 112.55M | 101M | 95.67M | 103.91M | 128.85M |
| Total Debt | 67.45M | 67.43M | 69.29M | 68.69M | 67.63M |
| Net Debt | 34.7M | 52.14M | 38.27M | 41.13M | 32.08M |
AxoGen, Inc.
NASDAQ:AXGN
Intrinsic Alpha fair value
Locked
Current Price
$56.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.